Datasheet

Mouse mAb to **Alpha fetoprotein (AFP)**
Clone **C2**
Isotype **IgG1-κ**

Source

A BALB/c mouse was immunized with alpha fetoprotein isolated from serum of hepatoma patients.
Fusion partner: SP2/0.

Specifications

C2 has been characterized in the ISOBM TD-2 workshop and assigned by K. Nustad to group E of a cluster of 6 major epitopes of human alpha fetoprotein. Human alpha fetoprotein is an oncofetal protein of 70 kDa. It is expressed in fetal liver and is normally absent in health adult tissues. It is positive on all yolk sac tumors, on some other germ cell tumors and on hepatocellular carcinomas.



Figure 1: Fetal liver stained with C2 (paraffin)

Species reactivity

Positive: human, mouse.
Negative: cow, dog, rat.

Applications

C2 is excellent for IHC. In paraffin sections a citrate antigen retrieval step is advised. It can also be used in ELISA, the TD-2 workshop found C2 suitable for an AFP tumor marker test, both as solid phase as well as tracer antibody in combination with any antibody of epitope groups A, B, C, or D.

ELISA	Flow cytometry	Frozen sections	Immunofluorescence	Paraffin sections
+	+	+	+	Citrate

Format

Produced in tissue culture, contains no host Ig. Antibodies are affinity purified and presented in PBS with 0,02% sodium azide.
Stored at 4°C-8°C, shelf life is at least 24 months after purchase.

Dilution advice

- ELISA (solid phase: 0,1-100 µg/ml; tracer: 0,001-100 µg/ml for 30 min at RT).
- Flow cytometry (0,5-1,0 µg/million cells in 0,1 ml).
- Immunofluorescence (0,5-1 µg/ml).
- Immunohistology (formalin-fixed: 1-2 µg/ml for 30 min at RT: staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6,0, for 10-20 min followed by cooling at RT for 20 minutes).

Positive control

Hep-G2 cells, fetal liver or hepatocellular carcinoma.

Datasheet

References

- Tsung K., et al. *J. Immunol. Methods* **39**: 363-368 (1980).
- Michell B.et al. *Eur. J. Cancer Clin. Oncol.* **19**: 1239-1246 (1983).
- Yazova A.K. et al. *Immunol. Lett*. **25**: 325-330 (1990).
- Nustad K. Et al. *Tumor Biol* **19**: 293 -300 (1998).
- Yakimenko E.F. et al. *Tumor Biol* **19**: 301-309 (1998).